Bioxytran (BIXT) Amortizatization of Intangibles (2019 - 2024)
Bioxytran (BIXT) posted Amortizatization of Intangibles of $622781.0 for Q4 2024, up 2391.12% sequentially from $25000.0 in Q3 2024.
Bioxytran (BIXT) Amortizatization of Intangibles (2019 - 2024) Analysis & Trends
Bioxytran has reported Amortizatization of Intangibles for 5 years, with the latest figure at $622781.0 in Q4 2024.
- Quarterly Amortizatization of Intangibles changed N/A year-over-year to $622781.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $647781.0 (up 247.44% YoY) and the FY2024 annual result came in at $677781.0, up 94.41% from the prior year.
- Amortizatization of Intangibles improved to $622781.0 in Q4 2024 per BIXT's latest filing, from $25000.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $622781.0 in Q4 2024 and troughed at $1000.0 in Q3 2020.
- A 4-year average of $115536.4 and a median of $41425.0 in 2022 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2020 and 2021: Amortizatization of Intangibles tumbled 92.75% in 2020, then surged 2896.4% in 2021.
- Over 4 years, Amortizatization of Intangibles stood at $1000.0 in 2020, then soared by 2896.4% to $29964.0 in 2021, then tumbled by 52.4% to $14263.0 in 2022, then soared by 4266.41% to $622781.0 in 2024.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $622781.0, $25000.0, and $14263.0 for Q4 2024, Q3 2024, and Q4 2022 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 622,781.00 |
| Dec 31, 2024 | 622,781.00 |
| Sep 30, 2024 | 25,000.00 |
| Sep 30, 2024 | 25,000.00 |
| Dec 31, 2022 | 14,263.00 |
| Dec 31, 2022 | 14,263.00 |
| Sep 30, 2022 | 172,182.00 |
| Sep 30, 2022 | 172,182.00 |
| Jun 30, 2022 | 41,425.00 |
| Jun 30, 2022 | 41,425.00 |
| Mar 31, 2022 | 91,334.00 |
| Mar 31, 2022 | 91,334.00 |
| Dec 31, 2021 | 29,964.00 |
| Dec 31, 2021 | 29,964.00 |
| Sep 30, 2021 | 29,964.00 |
| Sep 30, 2021 | 29,964.00 |
| Sep 30, 2020 | 1,000.00 |
| Sep 30, 2020 | 1,000.00 |
| Jun 30, 2020 | 76,265.00 |
| Jun 30, 2020 | 76,265.00 |